1. Associations between the ALSFRS‐R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS‐R scores in clinical studies MCI186‐16, MCI186‐17, and MCI186‐19. Issue 5 (2nd September 2022) Authors: Takahashi, Fumihiro; Kano, Osamu; Nagano, Yoshito; Yoneoka, Takatomo; Nelson, Sally; Ushirogawa, Yoshiteru Journal: Muscle & nerve Issue: Volume 66:Issue 5(2022) Page Start: 593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186‐16, MCI186‐17, and MCI186‐19. Issue 5 (2nd September 2022) Authors: Takahashi, Fumihiro; Kano, Osamu; Nagano, Yoshito; Yoneoka, Takatomo; Nelson, Sally; Ushirogawa, Yoshiteru Journal: Muscle & nerve Issue: Volume 66:Issue 5(2022) Page Start: 583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Issue 7 (December 2014) Authors: Abe, Koji; Itoyama, Yasuto; Sobue, Gen; Tsuji, Shoji; Aoki, Masashi; Doyu, Manabu; Hamada, Chikuma; Kondo, Kazuoki; Yoneoka, Takatomo; Akimoto, Makoto; Yoshino, Hiide; on behalf of The Edaravone ALS Study Group Journal: Amyotrophic lateral sclerosis and frontotemporal degeneration Issue: Volume 15:Issue 7/8(2014) Page Start: 610 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗